display
The laboratory service provider Synlab wants to go public on the Frankfurt Stock Exchange.
The listing in the Prime Standard should take place in the second quarter, announced the company on Wednesday in Munich.
The exact date depends on the development of the market environment.
Synlab is aiming for gross proceeds of EUR 400 million from the IPO.
Among other things, the money will be used to reduce debts.
The offer will include newly issued shares from a capital increase as well as shares from existing shareholders.
As early as mid-February, there was speculation on the market that the current owner, the holding company Cinven, would put the company on the stock exchange after Easter.
The reason for this is the high demand for health service providers among investors during the corona pandemic.
In concrete terms, Synlab is currently benefiting greatly from the demand for PCR tests for the coronavirus.
In the past year, sales and profits soared.
In February, insiders spoke of a possible total valuation of up to six billion euros.
display
Cinven had already hired the investment banks Goldman Sachs and JP Morgan in the fall to organize the IPO.
The holding company had acquired Synlab six years ago for 1.7 billion euros from the financial investor BC Partners and then merged with the French competitor Labco.
The company, based in Munich, currently employs around 20,000 people according to its own information and had sales of more than 2.6 billion euros in 2020.
With more than 500 million tests performed annually, it has become the largest European laboratory operator.